PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 5, 2026BioDrugs0 citationsOpen Access

Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent dMMR Endometrial Cancer: A Nationwide Cohort Study in France

ASAllison SingierConservatoire National des Arts et MétiersSVStéphane VignotAgence Nationale de Sécurité du Médicament et des Produits de SantéDDDavid DesplasConservatoire National des Arts et Métiers

Key Points

  • The aim is to assess the real-world effectiveness of dostarlimab combined with chemotherapy for advanced or recurrent dMMR endometrial cancer.
  • Nationwide cohort study conducted in France
  • Involved older and more comorbid patients
  • Compared with previous RUBY data for context
  • Survival outcomes were found to be less favorable compared to previous studies
  • The safety profile remained comparable to prior assessments

Abstract

This first real-world study of dostarlimab plus chemotherapy in advanced or recurrent endometrial cancer involved an older, more comorbid, and less selected population with more advanced disease than in RUBY. Survival outcomes were less favorable, but the safety profile was comparable.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Singier et al. (2026) studied this question.

synapsesocial.com/papers/69a91e57d6127c7a504c24behttps://doi.org/10.1007/s40259-026-00768-y
Ask AI
Helpful
Bookmark
Share
View Full Paper